A Phase Iii Randomized Open Label Study Comparing Bempegaldesleukin (Nktr-214) Plus Nivolumab To Sunitinib Or Cabozantinib (Investigator'S Choice) In Patients With Previously Untreated Advanced Renal Cell Carcinoma.
JOURNAL OF CLINICAL ONCOLOGY（2019）
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要